ALTEOGEN Inc.

KOSDAQ:A196170 Stock Report

Market Cap: ₩17.7t

ALTEOGEN Valuation

Is A196170 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of A196170 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: A196170 (₩330500) is trading below our estimate of future cash flow value (₩379793.99)

Significantly Below Future Cash Flow Value: A196170 is trading below future cash flow value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A196170?

Key metric: As A196170 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A196170. This is calculated by dividing A196170's market cap by their current earnings.
What is A196170's PE Ratio?
PE Ratio140.4x
Earnings₩125.93b
Market Cap₩17.69t

Price to Earnings Ratio vs Peers

How does A196170's PE Ratio compare to its peers?

The above table shows the PE ratio for A196170 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.9x
A068270 Celltrion
40x21.24%₩41.2t
A214450 PharmaResearch
21.1x23.08%₩3.2t
A145020 Hugel
19.6x20.24%₩2.7t
A290650 L&C BIOLTD
22.9x38.72%₩1.8t
A196170 ALTEOGEN
140.4x80.19%₩17.7t

Price-To-Earnings vs Peers: A196170 is expensive based on its Price-To-Earnings Ratio (140.4x) compared to the peer average (25.9x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does A196170's PE Ratio compare vs other companies in the KR Biotechs Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
A005250 Green Cross Holdings
4.8xn/aUS$411.96m
A377740 BioNote
4.6xn/aUS$360.89m
No more companies available in this PE range
A196170 140.4xIndustry Avg. 25.9xNo. of Companies4PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A196170 is expensive based on its Price-To-Earnings Ratio (140.4x) compared to the KR Biotechs industry average (26.8x).

Price to Earnings Ratio vs Fair Ratio

What is A196170's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A196170 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio140.4x
Fair PE Ratio86.8x

Price-To-Earnings vs Fair Ratio: A196170 is expensive based on its Price-To-Earnings Ratio (140.4x) compared to the estimated Fair Price-To-Earnings Ratio (86.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A196170 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩330,500.00
₩435,000.00
+31.62%
26.69%₩570,000.00₩250,000.00n/a4
Mar ’27₩407,500.00
₩435,000.00
+6.75%
26.69%₩570,000.00₩250,000.00n/a4
Feb ’27₩413,000.00
₩482,500.00
+16.83%
26.35%₩620,000.00₩290,000.00n/a4
Jan ’27₩449,500.00
₩522,000.00
+16.13%
31.58%₩730,000.00₩270,000.00n/a5
Dec ’26₩542,000.00
₩522,000.00
-3.69%
31.58%₩730,000.00₩270,000.00n/a5
Nov ’26₩488,500.00
₩522,000.00
+6.86%
31.58%₩730,000.00₩270,000.00n/a5
Oct ’26₩458,000.00
₩522,000.00
+13.97%
31.58%₩730,000.00₩270,000.00n/a5
Sep ’26₩455,000.00
₩514,000.00
+12.97%
31.29%₩730,000.00₩270,000.00n/a5
Aug ’26₩422,000.00
₩565,000.00
+33.89%
29.20%₩730,000.00₩400,000.00n/a2
Jul ’26₩372,500.00
₩565,000.00
+51.68%
29.20%₩730,000.00₩400,000.00n/a2
Jun ’26₩330,000.00
₩565,000.00
+71.21%
29.20%₩730,000.00₩400,000.00n/a2
May ’26₩351,000.00
₩565,000.00
+60.97%
29.20%₩730,000.00₩400,000.00n/a2
Apr ’26₩371,500.00
₩565,000.00
+52.09%
29.20%₩730,000.00₩400,000.00n/a2
Mar ’26₩387,000.00
₩565,000.00
+45.99%
29.20%₩730,000.00₩400,000.00₩407,500.002
Feb ’26₩371,500.00
₩565,000.00
+52.09%
29.20%₩730,000.00₩400,000.00₩413,000.002
Jan ’26₩309,500.00
₩565,000.00
+82.55%
29.20%₩730,000.00₩400,000.00₩449,500.002
Dec ’25₩280,000.00
₩476,666.67
+70.24%
38.54%₩730,000.00₩300,000.00₩542,000.003
Nov ’25₩356,500.00
₩271,666.67
-23.80%
36.08%₩375,000.00₩140,000.00₩488,500.003
Oct ’25₩327,000.00
₩271,666.67
-16.92%
36.08%₩375,000.00₩140,000.00₩458,000.003
Sep ’25₩319,000.00
₩271,666.67
-14.84%
36.08%₩375,000.00₩140,000.00₩455,000.003
Aug ’25₩319,000.00
₩271,666.67
-14.84%
36.08%₩375,000.00₩140,000.00₩422,000.003
Jul ’25₩277,500.00
₩246,666.67
-11.11%
30.58%₩300,000.00₩140,000.00₩372,500.003
Jun ’25₩185,900.00
₩201,250.00
+8.26%
50.81%₩300,000.00₩65,000.00₩330,000.004
May ’25₩176,900.00
₩168,333.33
-4.84%
58.22%₩300,000.00₩65,000.00₩351,000.003
Apr ’25₩186,300.00
₩168,333.33
-9.64%
58.22%₩300,000.00₩65,000.00₩371,500.003
Mar ’25₩160,600.00
₩168,333.33
+4.82%
58.22%₩300,000.00₩65,000.00₩387,000.003
₩435k
Fair Value
24.0% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/23 03:40
End of Day Share Price 2026/03/23 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ALTEOGEN Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyonseok KimCLSA
null nullDBS Bank Ltd
Haesoon KwonEugene Investment & Securities Co Ltd.